Q-Line Biotech Limited IPO Details
Factual IPO information from public filings. Not investment advice.
Issue Details
- Price Band
- ₹326 – ₹343
- Lot Size
- 400 shares
- Min. Investment
- ₹1,37,200
- Total Issue Size
- ₹214.48 Cr
- 62,53,200 shares
- Fresh Issue
- ₹214.48 Cr
- 62,53,200 shares
- Offer for Sale
- ₹0 Cr
- Face Value
- ₹10 per share
- Issue Type
- Book-built IPO
- Listing At
- NSE SME
- Shares Pre-Issue
- 1,70,74,999
- Shares Post-Issue
- 2,33,28,199
Lot Size & Investment
1 lot = 400 shares
Retail (min)
2 lots · 800 shares
Retail (max)
2 lots · 800 shares
S-HNI (min)
3 lots · 1,200 shares
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 2 | 800 | ₹2,74,400 |
| Small HNI (S-HNI) | 3 | 1,200 | ₹4,11,600 |
| Big HNI (B-HNI) | 8 | 3,200 | ₹10,97,600 |
Financial Performance
Restated figures in ₹ crore, unless stated otherwise
| Period | Dec-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| Assets | 561.34 | 455.49 | 339.25 | 251.58 |
| Total Income | 236.5 | 322.58 | 206.45 | 184.81 |
| Profit After Tax | 38.69 | 28.13 | 34.44 | 32.1 |
| EBITDA | 64.23 | 71.32 | 37.63 | 32.98 |
| Net Worth | 229.16 | 189.95 | 161.81 | 127.37 |
| Reserves & Surplus | 212.89 | 188.37 | 160.24 | 125.79 |
| Total Borrowing | 243.85 | 164.95 | 96.91 | 73.65 |
Key Performance Indicators
| Period | Dec-25 | Mar-25 |
|---|---|---|
| ROE (%) | 16.88 | 23.74 |
| ROCE (%) | 13.32 | 17.66 |
| EPS (₹) | — | 16.47 |
| P/E (pre-issue) | — | 20.82 |
| P/E (post-issue) | — | 15.51 |
About Q-Line Biotech Limited
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company's key manufacturing segments include indigenous manufacturing of reagents (Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others [POC Devices & Rapid Tests]) and supplying/manufacturing of in-vitro diagnostics (IVD) and Pathology equipment & devices. As of December 31, 2025, the total annual capacity was about 1.4 million kits (Haematology, Clinical Chemistry, Rapid/Elisa) and 1,200 Selectra Machines. As on March 31, 2026, the company had 362 permanent employees. Competitive Strengths : Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control. Diversified product portfolio with focus on IVD industry Widespread distribution network with a presence across all four regions. Long standing relationships with customers. Experienced Promoter and Management team
Company Information
- Book running lead managers
- Hem Securities Ltd.
- Share India Capital Services Pvt.Ltd.
- Registered office
- 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, 226012
- Market maker
- Hem Finlease Pvt.Ltd.